Mantle cell lymphoma is a rare type of blood cancer, which occurs due to excessive growth of lymphocytes. Mantle cell lymphoma is one of the B-cell non-Hodgkin lymphoma, which occurs as a result of formation of tumors in the lymph nodes, which enters the blood and spreads to the bone marrow, digestive tract, spleen, and liver. Common symptoms of the disease include loss of appetite, weight loss, fever, nausea, and vomiting. The type of treatment for a patient suffering from mantle cell lymphoma depends on various factors such as the stage of disease, age, and overall health of the patient. In 2012, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy.
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1148
Rising prevalence of mantle cell lymphoma is expected to accelerate growth of the mantle cell lymphoma treatment market over the forecast period
Major factors driving growth of the mantle cell lymphoma market are rising prevalence of mantle cell lymphoma and increasing research and development activities in the healthcare sector resulting in a promising product pipeline. According to the study by Drug Development Technology, 2017, an estimated 3,300 new cases of mantle cell lymphoma are diagnosed every year in the U.S. The mantle cell lymphoma treatment market is expected to gain significant traction with the approval from the federal agencies. For instance, in October 2017, AstraZeneca received approval for Calquence under the FDA’s accelerated approval pathway for the treatment of adults with mantle cell lymphoma. Also, development of targeted agents with low toxicity profiles for the treatment of relapsed mantle cell lymphoma in combination with approved drugs is a major factor augmenting the mantle cell lymphoma treatment market growth. However, serious side effects of the drugs such as anemia, neutropenia, and diarrhea are the factors restraining growth of the mantle cell lymphoma treatment market.
Click To Continue Reading On Mantle Cell Lymphoma Treatment Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]